Friday, July 10, 2026

pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.

Tour Hekla

Tour Hekla clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
Status
Public
HQ
Puteaux, Ile de France 92800, FR
Employees
6
Programs
27
Drugs
71
Patents
0
Intelligence · Clinical Programs

Tour Hekla projects

12 ClinicalTrials.gov programs sponsored by Tour Hekla.

Tour Hekla has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. DR220204

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial
  2. DR220214

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial
  3. DR230070

    Tour Hekla

    Prevention of post-traumatic stress disorder

    phase 2 small molecule active

    1 trial
  4. DR230330 – ANRS0514s

    Tour Hekla

    Healthy volunteers

    phase 2 small molecule active

    1 trial
  5. IVAMI

    Tour Hekla

    patients with stable coronary artery disease

    phase 2 small molecule active

    1 trial
  6. KALINOX 50%/50% for Treatment of suicidal ideation

    Tour Hekla

    Treatment of suicidal ideation

    phase 2 small molecule active

    1 trial
  7. OPDIVO for Unresectable locally advanced o…

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial
  8. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial
  9. SOGUG2020IEC(VEJ)11

    Tour Hekla

    Muscle-invasive bladder cancer (MIBC)

    phase 2 small molecule active

    1 trial
  10. TOUR006-T01

    Tour Hekla

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial
  11. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial
  12. Xarelto 2.5 mg film-coated tablets

    Tour Hekla

    Chronic hemodialysis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Tour Hekla have?

12 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.